Travere Therapeutics (TVTX) Tops Q2 EPS by 14c

Travere Therapeutics (NASDAQ: TVTX) reported Q2 EPS of ($0.65), $0.14 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $54.12 million versus the consensus estimate of $50.4 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• Netflix climbs following Ackman stake, up 1.8%
• BK Technologies (BKTI) Tops Q2 EPS by 11c
• McGraw Hill (MH) Tops Q2 EPS by 11c, Beats on Revenue; Offers FY26 Guidance